Table 1 Baseline patient characteristics
Before matching | Matched population | |||||
|---|---|---|---|---|---|---|
Repeat DCB | De novo DCB | p-value | Repeat DCB | De novo DCB | p-value | |
n = 54 | n = 517 | n = 49 | n = 49 | |||
Age, years | 75.4 ± 8.1 | 77.1 ± 9.2 | 0.19 | 75.3 ± 7.8 | 77.4 ± 9.4 | 0.232 |
Male sex | 57% (31) | 58% (302) | 0.886 | 53% (26) | 49% (24) | 0.686 |
Body mass index, kg/m2 | 22.4 ± 4.8 | 22.6 ± 3.8 | 0.806 | 21.9 ± 4.6 | 24.2 ± 4.8 | 0.027 |
Ambulatory | 70% (37) | 71% (366) | 0.831 | 71% (35) | 59% (29) | 0.203 |
Current smoker | 15% (8) | 23% (110) | 0.166 | 10% (5) | 19% (8) | 0.248 |
Hypertension | 92% (49) | 85% (441) | 0.161 | 94% (46) | 88% (43) | 0.243 |
Dyslipidemia | 72% (38) | 65% (336) | 0.345 | 69% (34) | 84% (41) | 0.095 |
Diabetes mellitus | 57% (31) | 52% (268) | 0.452 | 61% (30) | 61% (30) | – |
Chronic kidney disease | 64% (34) | 61% (315) | 0.671 | 63% (31) | 69% (34) | 0.521 |
Hemodialysis | 26% (14) | 19% (99) | 0.217 | 26% (13) | 24% (12) | 0.817 |
Cerebrovascular disease | 17% (9) | 19% (98) | 0.702 | 20% (10) | 10% (5) | 0.161 |
Coronary artery disease | 81% (43) | 57% (291) | < 0.001 | 80% (39) | 71% (35) | 0.347 |
Heart failure | 17% (9) | 15% (75) | 0.654 | 16% (8) | 19% (9) | 0.754 |
Aspirin | 89% (48) | 79% (407) | 0.077 | 92% (45) | 86% (42) | 0.337 |
P2Y12 inhibitor | 93% (50) | 73% (376) | 0.001 | 94% (46) | 100% (49) | 0.121 |
Cilostazol | 17% (9) | 19% (101) | 0.611 | 10% (5) | 6% (3) | 0.357 |
Anticoagulant | 24% (13) | 15% (79) | 0.094 | 20% (10) | 20% (10) | – |
Statin | 61% (33) | 51% (264) | 0.164 | 59% (29) | 62% (30) | 0.738 |